Objective and results of the project:

Migrevention's wider vision for the UK market is for the digital headache clinic solution to be recognized by the NHS as a best practice standard and to be widely adopted across the UK healthcare system (at least 25% of relevant NHS hospitals and clinics by 2029).

The purpose of the business model testing project is to carry out the necessary prerequisite activities that would ensure market access and provide an opportunity for a full-scale launch of the product in the UK healthcare system in 2025.

The expected results in support of the objective in the next 12 months are as follows:

• Carrying out the initial validation of the product in the UK market in a clinical environment (service evaluation process)

• Developing a sales strategy and sustainable growth model for active expansion across the NHS network

• Conducting a Product Technology Assessment (DTAC) process in the UK for regulatory approval

Project implementation period: 01.01.2024-31.12.2024

Project grant: 48 825 EUR (The project is financed from the state budget from the means of financing research and development activities)

Project total amount: 65 100 EUR

Project contacts